Showing results for: clinical drug development News
-
Mechanism of Action Via Inovotion’s Assays
Understanding Mechanisms of Action is a key success factor in developing new anticancer drugs. It’s needed to optimize drug development, clinical trials, and regulatory approval. Inovotion’s in vivo assays provide ample access to tumors for deep analysis of the mechanisms of action including transcriptomics, metabolomics, proteomics, immune cell infiltration, histological analysis, ...
-
Nova discovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development
Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jinko®, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with ...
-
Creative Proteomics Introduces Innovative Absolute Quantification (AQUA) Service for Precise Protein Quantification Analysis
Creative Proteomics, a leading global provider of proteomics services, is proud to announce the launch of its innovative Absolute Quantification (AQUA) service, offering scientists a highly accurate solution for protein quantification analysis. This groundbreaking service will play a crucial role in life science research, drug development, and clinical diagnostics. Absolute Quantification (AQUA) ...
-
Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts
Thermo Fisher Scientific Inc., the world leader in serving science, officially opened its new $90 million viral vector CDMO (contract development and manufacturing organization) site in Lexington, Mass. The 50,000-square-foot facility will add more than 200 jobs and support the development, testing and manufacture of viral vectors, which are critical to advancing new life-saving gene and cell ...
-
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it will host a virtual fireside chat with its Chief Medical Officer, Dr. Bob Dagher, on Tuesday, May 17, 2022 at 10:00 a.m. EDT. Dr. Bob Dagher has over 20 years ...
-
CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies
TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the ...
By CytoReason
-
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. (“FutureChem”) (KOSDAQ: 220100ks), a leading ...
-
Symberix Awarded $2 Million from National Institutes of Health to Support Lead Program
Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. ...
-
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. (“Acanna”), by way of ...
-
Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
-
Agilent Technologies Presents Thought Leader Award to Renowned Systems Pharmacologist Lawrence Lesko
Agilent Technologies Inc. (NYSE: A) announced today that Dr. Lawrence J. Lesko has received an Agilent Thought Leader Award in support of his research into preclinical toxicological assessments of new medicines. An internationally recognized pharmacologist, Dr. Lesko directs the Center for Pharmacometrics and Systems Pharmacology at the University of Florida's College of Pharmacy in Orlando. ...
-
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. CTT1403 is a peptidomimetic drug that targets Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate ...
-
Rapid development of Precision medical Continuous attention to medical equipment
Market review for last week In Sector, Shanghai and Shenzhen index (2015/3/9-2015/3/13) up 3.36% last week, all the plates in the bank, computer up front, better medicine plates, up 2.82%. Medicine in each sector, the best of medical equipment, or 6.21%, medical services (4.85%), traditional Chinese medicine (3.14%) and business (3.07%) were relatively good medicine, biological products (2.29%) ...
-
Creative Proteomics Introduces Methionine Cycle Analysis Service for Metabolomics Research
Creative Proteomics, a leading provider of advanced proteomics and metabolomics services, is proud to announce the launch of its innovative Methionine Cycle Analysis Service. This service represents a significant leap forward in the field of metabolomics, providing researchers with a powerful tool to unravel the complexities of metabolic pathways. Methionine, a pivotal amino acid, is central to ...
-
Aker BioMarine Hires Two Top Scientists to Strengthen its R&D Initiatives
Aker BioMarine, a global biotech innovator and world-leading supplier of krill, announces two new talents on the Human Nutrition team. Katina Handeland, PhD., and Yunpeng Ding, PhD. have both joined Aker BioMarine as Directors for Research & Development (R&D). They will be responsible for research within the company’s human health and nutrition department. “We are thrilled to ...
-
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype. The ...
By CytoReason
-
Fc Fusion Protein Production Service Now Available at Profacgen
Profacgen, a state-of-the-art protein service provider located in the USA, provides comprehensive one-stop services for pre-clinical drug development, aiming to evaluate and improve the efficacy and safety of new drug candidates. Now, Profacgen can provide soluble Fc fusion protein to applicate in various fields. Fc fusion protein refers to a new type of protein produced by using genetic ...
By Profacgen
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
Novadiscovery strengthens leadership team with senior appointments
Novadiscovery, a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces that it has strengthened its leadership team with two senior appointments. Jim Bosley has been appointed as Senior Vice President, Modeling and Simulation and Charlotte Turnier has been appointed as Senior Vice President, Sales and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you